Total
0
Shares
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating
CEO & Managing Director, Dr Tony Keating
Source: Courier Mail
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ResApp Health (RAP) has launched its respiratory diagnostic test, ResAppDx, on select Android devices
  • This launch follows thorough testing, and the app is now available on the Samsung Galaxy S9, S10 and S20 devices
  • This testing was designed to ensure ResAppDx’s algorithms had the required level of accuracy for each make and model of the phone
  • ResAppDx uses machine learning algorithms to analyse a patients cough sounds to diagnose disease and provide quick and accurate information
  • ResApp is now in the process of launching ResAppDx for Android through its existing partners and further launches on other devices are planned for the near-term
  • Company shares up 9.52 per cent on the market this morning and are trading for 11.5 cents each

ResApp Health (RAP) has launched its respiratory diagnostic test, ResAppDx, on select Android devices.

This launch follows thorough testing, and the app is now available on the Samsung Galaxy S9, S10 and S20 devices.

This testing was designed to ensure that ResAppDx’s algorithms had the required level of accuracy for each make and model of the phone.

Multiple new testing procedures and algorithms were needed to ensure the test would be perform similar on each device.

ResApp is now in the process of launching ResAppDx for Android through its existing partners and further launches on other devices are planned for the near-term.

“Launching ResAppDx on select Android devices is a major achievement for ResApp. The company has undertaken extensive testing to ensure our offering continues to meet the high standards set by regulative bodies and provides clinicians with best in class solution to test for respiratory disease,” CEO and Managing Director Dr Tony Keating said.

“We anticipate that the launch for Android users will considerably broaden our potential patient base and look forward to launching SleepCheck for Android,” he added.

ResAppDx is ResApp’s mobile software app which is used by clinicians for the diagnosis of multiple respiratory problems.

It uses machine learning algorithms to analyse a patient’s cough sounds and diagnose the disease and provide quick and accurate information.

It is a software-only solution that runs on smartphones, meaning it does not require any additional hardware or accessories.

ResApp is up 9.52 per cent on the market this morning with shares trading for 11.5 cents each at 11:24 am AEDT.

RAP by the numbers
More From The Market Herald
Amplia Therapeutics - CEO and MD, John Lambert

" Amplia Therapeutics (ASX:ATX) granted $2.1 million R&D cash flow loan

Amplia Therapeutics (ATX) has been granted a $2.1 million Research and Development (R&D) cash flow loan.
Creso Pharma (ASX:CPH) - Creso Pharma

" Creso Pharma’s (ASX:CPH) Halucenex secures Dealer’s Licence amendment

Halucenex Life Sciences, a subsidiary of Creso Pharma (CPH), has secured an amendment to its Controlled Drugs and Substances Dealer’s Licence.

" Immutep (IMM) treats first five patients in solid tumour study

Immutep (IMM) has treated five patients in its study evaluating eftilagimod (efti) alpha in conjunction with standard of care chemotherapy.
Zelira Therapeutics (ASX:ZLD) - CEO and MD, Dr Oludare Odumosu

" Zelira Therapeutics (ASX:ZLD) granted ethics approval for chronic pain trial

Zelira Therapeutics (ZLD) has received ethics approval for its Phase 2a clinical trial for chronic pain.